v3.22.2.2
Note 9 - Stockholders' Deficit
 6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

9. Stockholders’ Deficit

 

The Company has granted options to employees and Board members to purchase shares of common stock. The following is a summary of option award activity during the six months ended June 30, 2022:

    

   

Total Stock Options Outstanding

     Weighted Average Exercise Price per Share  

December 31, 2021

     45,468     $ 14.28  

Granted

     1,216,149       0.24  

Vested

     —       —  

Forfeited, Canceled

     (26,730 )     14.89  

June 30, 2022

     1,234,887     $ 0.44  

 

The following is a summary of outstanding stock options as of June 30, 2022:

 

   

As of June 30, 2022

  
    Stock Options Outstanding     Vested Stock Options  

Quantity

     1,234,887       1,234,887  

Weighted Average Exercise Price

   $ 0.44     $ 0.44  

Weighted Average Remaining Contractual Term (in Years)

     9.90       9.90  

Intrinsic Value

   $ —     $ —  

 

As of June 30, 2022, there was no total compensation cost not yet recognized related to unvested stock options.

 

As of June 30, 2022, there are 561,602 restricted stock units outstanding to employees from the old Cytocom plan.